При пациенти с диабет тип 1, малките разлики между терапевтичните групи (0, 010 L, пр
In type 1 subjects, resolution of small treatment group differences (0.010L favouring comparator) occurred within 2 weeks of EXUBERA cessation following 12 weeks of therapy.